key: cord-0962950-7wp3clc3
authors: d'Etienne, James P.; Alanis, Naomi; Chou, Eric; Garrett, John S.; Kirby, Jessica J.; Bryant, David P.; Shaikh, Sajid; Schrader, Chet D.; Wang, Hao
title: Validation of a simplified comorbidity evaluation predicting clinical outcomes among patients with coronavirus disease 2019 – A multicenter retrospective observation study
date: 2022-03-10
journal: Am J Emerg Med
DOI: 10.1016/j.ajem.2022.03.011
sha: 94fe91308d7156ea3ad5bbe44d142cd54784cd36
doc_id: 962950
cord_uid: 7wp3clc3

OBJECTIVES: We compared and validated the performance accuracy of simplified comorbidity evaluation compared to the Charlson Comorbidity Index (CCI) predicting COVID-19 severity. In addition, we also determined whether risk prediction of COVID-19 severity changed during different COVID-19 pandemic outbreaks. METHODS: We enrolled all patients whose SARS-CoV-2 PCR tests were performed at six different hospital Emergency Departments in 2020. Patients were divided into three groups based on the various COVID-19 outbreaks in the US (first wave: March–May 2020, second wave: June–September 2020, and third wave: October–December 2020). A simplified comorbidity evaluation was used as an independent risk factor to predict clinical outcomes using multivariate logistic regressions. RESULTS: A total of 22,248 patients were included, for which 7023 (32%) patients tested COVID-19 positive. Higher percentages of COVID-19 patients with more than three chronic conditions had worse clinical outcomes (i.e., hospital and intensive care unit admissions, receiving invasive mechanical ventilations, and in-hospital mortality) during all three COVID-19 outbreak waves. CONCLUSIONS: This simplified comorbidity evaluation was validated to be associated with COVID clinical outcomes. Such evaluation did not perform worse when compared with CCI to predict in-hospital mortality.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19) is a worldwide pandemic. Due to its variant strains, the prevalence and mortality of COVID-19 vary across different geographic locations at different time points (waves/outbreaks). 1-3 Among all COVID-19 patients, risk factors predicting the severity of COVID-19 were reported during the early phase of COVID pandemics in many studies. [4] [5] [6] [7] [8] [9] The most commonly reported risk factors of mortality include age (≥65), gender (male), patients with lower socioeconomic status (SES), and patients having different comorbidities. [4] [5] [6] [7] [8] [9] Together, these risk factors predict mortality and worse clinical outcomes. 7, 10 As an independent risk, patient comorbidity was reported to predict patient clinical outcomes. 11, 12 These outcomes range from requiring hospitalization, intensive care unit (ICU) admission, invasive mechanical ventilation (IMV), to all-cause in-hospital mortality. However, previous studies showed inconsistent findings for patients with different chronic conditions in terms of clinical outcome predictions. 4, 13, 14 The inconsistent results made the investigators consider using an established disease index for overall comorbidity assessment. The two most common comorbidity indexes, the Charlson Comorbidity Index (CCI) and Elixhauser Comorbidity Index (ECI), have been used to determine COVID severity. 15, 16 Although the CCI and ECI were not initially designed for COVID severity prediction, their overall COVID severity outcome predictions were fairly consistent. 15, 17, 18 However, calculating these two comorbidity indexes is complicated. Many chronic diseases were not reported to be directly associated with COVID severity (i.e., peptic ulcer disease). As such, a novel simplified comorbidity index (CCC: COVID-related high-risk Chronic Conditions) was reported recently. 19 This simple comorbidity index first screened all potential chronic diseases associated with COVID severity cited in previous reports, then used the number of chronic diseases patients suffered as a possible indicator for clinical outcome predictions. 19 The study showed that its performance accuracy was not inferior to those of the CCI or ECI, 19 meaning it did not perform worse than the CCI or ECI. However, this was a single-center study without larger-scale external validations.

During the COVID pandemic in the US (though its prevalence varied at different time-points in different geographic locations), there were several waves of COVID outbreaks in 2020. 20, 21 In the state of Texas, the first wave (1 st wave) was defined as patients presented at EDs from March 1 st to May 31 st , 2020. The second wave (2 nd wave) was defined as patients presented at EDs from June 1 st to September 30 th , 2020. The third wave (3 rd wave) was defined as patients presented at EDs from October 1 st to December 31 st , 2020.These outbreak waves are based on local COVID statistics, [22] [23] [24] epidemiological and mathematical analysis, 20, 21 and Texas COVID case statistic reports. 26 Though the etiologies of these outbreaks are still not fully understood, it may, in part, be associated with certain SARS-CoV-2 variant strains. 1, 3, 27 We understand we are still in the process of learning COVID-19 management, especially as different SARS-CoV-2 variant strains present themselves. During the early COVID-19 pandemic (i.e., first wave), few effective treatments were available, and most patients received only supportive care. However, novel medications and treatments became available during the third pandemic wave. 34, 35 Therefore, some risk factors initially used to predict clinical outcomes during the early phase of the COVID-19 pandemic may no longer be risk factors with the improvement of COVID-19 management.

It is essential to understand the role of comorbidity during different outbreak waves in predicting COVID-19 disease severity. At ED, with surges of COVID-positive patients, determining an appropriate J o u r n a l P r e -p r o o f disposition becomes challenging. With limited hospital and intensive care unit beds, not every patient can be admitted to the hospital. ED physicians have to decide which patients get the most benefit from hospital admission. The proper outcome predictions by prediction models, will allow ED physicians to recognize the disease progress earlier, thus making appropriate patient dispositions and treatments, and further advocating the necessity of receiving vaccinations. In addition, with likely SARS-CoV-2 variant strains and many COVID outbreaks, it is also important to understand further potential risk changes for COVID-19 severity predictions. Therefore, in this study, we aim to 1) externally validate a novel comorbidity evaluation (CCC) compared to the Charlson Comorbidity Index to predict COVID-19 clinical outcomes in a multi-center setting; and 2) determine the changes of comorbidity risk predicting patient in-hospital mortality during different COVID-19 pandemic waves.

This is a multi-center retrospective observational study. We enrolled patients from Emergency Departments (ED) of six different hospitals, including one urban publicly funded hospital and other urban/suburban community hospitals. Among all six hospitals, two are tertiary referral centers and level one trauma centers located in North Texas, USA. The study procedure was designed in compliance with the Declaration of Helsinki. This study was approved by each institution's respective Institutional Review Board, with waived informed consent (No. 1614030-1 & 344143).

From March 1 to December 31, 2020, we included all patients who presented to EDs with positive SARS-CoV-2 polymerase chain reaction (PCR) tests indicating COVID-19 infections. We exclude ones with unknown dates/times of ED visits and exclude missing information from key variables (i.e., age).

Study data were retrieved from the electronic medical record (EMR) by dedicated persons from the Department of Information Technology. They received sufficient data management training and were initially blinded to this study (i.e., before the aggregated data was open to all participants in this project). We also randomly selected 60 patient data three times from the entire dataset to manually check and validate the accuracy of data retrieval. severity from previous studies (e.g., ICU admissions, mortalities, etc.) 5, 7, 12, 28-31 , and 2) experts' opinions using a modified Delphi's technique 32 . These chronic conditions are included in Supplementary Table-1. General patient characteristics (age, gender, race/ethnicity) were also analyzed in this study. We divided age into three groups: 1) <40; 2) 40-65; 3) ≥65 years old. Race/ethnicity is categorized based on the Federal Statistics and Program administrative reporting of basic racial and ethnic categories. We divided the patients into four groups: 1) Non-Hispanic White (NHW); 2) Non-Hispanic Black (NHB); 3) Hispanic/Latino (Hispanic), and 4) others. Due to the relatively small sample size of "other" race/ethnicities (including American Indian, Alaska Native, Asian, Native Hawaiian, or other Pacific Islanders, unknown, or patient refusal), we categorized these patients into one group.

We divided COVID-19 pandemic outbursts of 2020 into three different waves based upon US national trends, Texas COVID case report statistics, and local reports. 22, 23, 26 These three waves were: the first wave (March 1 st to May 31 st , 2020), the second wave (June 1 st to September 30 th , 2020), and the third wave (October 1 st to December 31 st , 2020).

First, among the patients who tested positive for SARS-CoV-2-PCR, we determined the association between several chronic conditions that patients reported and patient clinical outcomes. We classified patients with chronic conditions into four categories: 1) patients with no chronic condition; 2) patients with one chronic condition; 3) patients with two chronic conditions; and 4) patients with three or more chronic conditions. We used the same comorbidity classification as previously reported and refer to it as the simplified comorbidity evaluation (CCC). 19 Second, to better determine if these chronic conditions predict severity of clinical outcomes, multivariate logistic regression was performed with the adjustments for other potential independent risks predicting clinical outcomes (i.e., age, sex, and race/ethnicity). Third, we measured the performance accuracy of the simplified comorbidity evaluation (CCC) in comparison to the CCI. The CCI has been previously used to predict severity of disease and patient in-hospital mortality. 33 

Analysis of variance (ANOVA) was used to compare clinical outcomes of different groups (e.g., different COVID-19 outburst waves). We used multivariate logistic regression analyses to identify patients with chronic condition(s) associated with four clinical outcomes by adjusting other variables (age, gender, race/ethnicity). Adjusted Odds Ratios (AOR) were reported with 95% confidence intervals (CI). AUC (area under the curve) was used to measure the performance accuracy of different comorbidity evaluations (i.e., simplified comorbidity evaluation and CCI) predicting in-hospital mortality. Investigators used STATA 16.0 (College Station, TX) for all statistical study analyses, with p<0.05 considered statistically significant.

age information. Among these 22,248 patients, a total of 7,023 patients were COVID-19 positive and placed in the final analysis. Table 1 lists patient general demographic characteristics and clinical metrics. We found that among all COVID-positive patients, Hispanics had the highest SARS-CoV-2-PCR positivity rate during all three COVID-19 pandemic waves. We also discovered fewer patients were admitted to the hospital (p<0.001) during the third wave. However, among those who were admitted to the hospital, they tended to be severe, with more patients requiring Intensive Care Unit (ICU) care (p=0.014) and Invasive Mechanical Ventilation (IMV, p<0.001) in comparison to the first two waves. All-cause in-hospital mortality shows no differences among the three pandemic waves (p=0.144, Table 1 ).

In this cohort, clinical outcomes worsened among COVID-19 positive patients with an increasing number of chronic conditions (CC). Patients with multiple CCs tended to be admitted to the hospital more, received ICU care and IMV, and yielded higher in-hospital mortality ( Table 2 , p<0.001). However, certain changes occurred during the different COVID-19 pandemic waves. For example, ED physicians tended to admit more patients during pandemic waves 1 and 2 compared to the third wave regardless of patient comorbidity statuses. With fewer patients admitted to the hospital during the third pandemic wave, this might subsequently result in relatively higher rates of ICU admissions, received IMV, and in-hospital mortality ( Table 2) .

Multivariate logistic regression was performed to further determine the relationship between the number of chronic conditions and the severity of in-hospital mortality, adjusting for all potential independent risks predicting clinical disease outcomes in previous reports (e.g., age, sex, race/ethnicity, and comorbidities). We found that age is one independent risk predicting in-hospital mortality during all three pandemic waves. In addition, though the Adjusted Odds Ratio (AOR) of chronic conditions predicting in-hospital mortality decreased from the first wave to the third wave, it still acted as one independent risk to predict mortality (Table 3) . Male acting as an independent risk to predict mortality occurred only during the second pandemic wave but not during the first and third waves. In general, race/ethnicity had no association with in-hospital mortality, especially during the third pandemic wave (Table 3) .

Finally, the Area Under the Curve (AUC) of simplified comorbidity evaluation (CCC) and CCI (Charlson Comorbidity Index) were compared to determine their performance accuracy on in-hospital mortality prediction. Results indicated similar performance accuracies for predicting in-hospital mortality during the 1 st and 2 nd COVID-19 pandemic waves. Interestingly, during the 3 rd COVID-19 pandemic wave, we found better performance accuracy on mortality prediction using simplified comorbidity evaluation than CCI (p=0.033, Table 4 ).

This study focused on validating a simplified comorbidity evaluation (CCC) to predict COVID-19 clinical outcomes among ED COVID-19 patients. A previous study showed that COVID-19 patients with fewer comorbidities had better clinical outcomes, including lower hospital general admissions, ICU admissions, requiring IMV, and in-hospital all-cause mortality. 19 Our study has validated these findings in a multicenter setting with different COVID-19 pandemic waves. More importantly, compared with the original J o u r n a l P r e -p r o o f tool, we found that the accurate prediction of COVID-19 severity gradually subsided among patients with only one or two chronic conditions. However, the accurate prediction of COVID-19 severity among patients with three or more chronic conditions remains unchanged, regardless of different pandemic waves. 1 Therefore, though more efficient COVID-19 managements emerged with the ongoing COVID-19 pandemic, the number of patients' comorbidities could still act as risk factors to predict clinical outcomes. In addition, the simplified comorbidity evaluation (CCC) is not inferior in predicting in-hospital mortality during different pandemic waves than the CCI. These findings indicate that when managing COVID-19 patients, special attention should be paid to those patients with three or more chronic conditions.

Apart from this, our study reexamined the potential risk factors affecting clinical outcomes among COVID-19 patients during different pandemic outbreaks. We found certain changes occurred on these risk factors predicting clinical outcomes. Some risks remained (e.g., elderly and comorbidity), while others no longer considered risks (e.g., sex and race/ethnicity). Such changes might be, in part, due to different SARS-CoV-2 variants, the emergence of novel management, or with the more understanding of COVID-19 by ED physicians. Therefore, some risk prediction tools that could predict COVID-19 severity under certain phases might not be reliable when the COVID-19 pandemic extended to other phases. A validation of this simplified comorbidity index (CCC) thus added its value when evaluated during different pandemic outbreaks among different EDs with diverse patient populations. We understand our findings only reflect the history. However, this study may serve as a foundation for validating COVID-19 severity predictions dynamically during different pandemic phases.

Although our study mainly focuses on comorbidity, other risk factors predicting clinical outcomes were investigated. Race/ethnicity has been considered one of the risks to predict COVID-19 severity in some studies during the early COVID-19 pandemic. 37, 38 When adjusted for other variables such as age and sex, our findings showed that race/ethnicity was no longer considered an independent risk predicting COVID-19 severity. 39, 40 Advanced age is reported to be one of the risks predicting COVID-19 severity in many studies. 5, 11 Our study had similar findings. . In some studies, the male gender was considered another risk predicting COVID-19 severity, 5, 7 while others did not . 11, 41 Our study showed variations during different waves. Its mechanism(s) are still unclear. We recommend that future larger-scale studies be performed to validate the patients' biographic features related to clinical outcomes. This study has several strengths: 1) This is a multi-site study. We enrolled ED COVID-19 patients at different ED settings (i.e., a public-funded hospital ED and urban/suburban community EDs); 2) Different comorbidities were analyzed. This study included 12 common comorbidities, which account for the most common comorbidities affecting COVID-19 severity in the current literature; and 3) a simplified comorbidity evaluation is compared with Charlson comorbidity index, which has been used and validated to determine disease severity during hospitalization. With these strengths, this study's findings could guide ED physicians in predicting disease severity and determining appropriate dispositions.

This study has its limitations. First, this is a retrospective study. Given the nature of the study design, we cannot avoid missing, incomplete, and incorrect information. Second, though this study enrolled over 22,000 patients, it may not have a large enough sample size in each group when investigators further divided into subgroups. In addition, this study only included data from March 1 to December 31, 2020, when the third pandemic was ongoing, and data might not reflect the actual conditions of the third pandemic wave. Our future study will perform an extended analysis to include all patients through 2021.

J o u r n a l P r e -p r o o f Third, we only had age, sex, race/ethnicity into our multivariate logistic regression model for clinical outcome prediction analysis. Other variables that could also affect clinical outcomes, such as socioeconomic statuses, household living conditions, were not analyzed. Fourth, this study enrolled only ED patients in North Texas. This might not reflect the COVID-19 patients' status in other geographic locations or different hospital settings. Last, this study only included patients with certain chronic conditions. We intended to validate an existing tool to predict clinical outcomes. However, we did not examine the potential impact of each chronic condition in relation to patients' clinical outcomes. Therefore, our findings should be interpreted with these considerations in mind. A large-scale multicenter prospective study is warranted for further validation.

A simplified comorbidity evaluation to predict COVID-19 severity has been validated. Its use to predict COVID-19 clinical outcomes has not changed significantly during different COVID-19 pandemic waves. 

The author(s) declare no competing interests.

The study data are available upon reasonable requesting to the corresponding author. J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f 

A Comprehensive Review of COVID-19 Virology, Vaccines, Variants, and Therapeutics

Emergence of European and North American mutant variants of SARS-CoV-2 in South-East Asia

Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom

Impact of age, sex, comorbidities and clinical symptoms on the severity of COVID-19 cases: A meta-analysis with 55 studies and 10014 cases

Epidemiological, comorbidity factors with severity and prognosis of COVID-19: a systematic review and meta-analysis

Isolation, social stress, low socioeconomic status and its relationship to immune response in Covid-19 pandemic context

Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy

The Impact of Socioeconomic Status on the Clinical Outcomes of COVID-19

a Retrospective Cohort Study

Risk factors for severe and critically ill COVID-19 patients: A review

Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study

Clinical Features and Outcomes of 105 Hospitalized Patients With COVID-19 in

Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis

Coronavirus disease (COVID-19): A systematic review and meta-analysis to evaluate the impact of various comorbidities on serious events

Association of cardiovascular disease and 10 other pre-existing comorbidities with COVID-19 mortality: A systematic review and meta-analysis

Prognosis models for severe and critical COVID-19 based on the Charlson and Elixhauser comorbidity indices

Charlson Comorbidity Index Score and Risk of Severe Outcome and Death in Danish COVID-19 Patients

Why Summary Comorbidity Measures Such As the Charlson Comorbidity Index and Elixhauser Score Work

Charlson comorbidity index and a composite of poor outcomes in COVID-19 patients: A systematic review and meta-analysis

A Simplified Comorbidity Evaluation Predicting Clinical Outcomes Among Patients With Coronavirus Disease

PolSIRD: Modeling Epidemic Spread Under Intervention Policies: Analyzing the First Wave of COVID-19 in the USA

Comparing mortalities of the first wave of coronavirus disease 2019 (COVID-19) and of the 1918-19 winter pandemic influenza wave in the USA

Viral Load of Severe Acute Respiratory Syndrome Coronavirus 2 in Adults During the First and Second Wave of Coronavirus Disease

Basic Demographic Parameters Help Predict Outcomes in Patients Hospitalized With COVID-19 During the First Wave of Infection in West Texas

Molecular Architecture of Early Dissemination and Massive Second Wave of the SARS-CoV-2 Virus in a Major Metropolitan Area

Bracing for the Wave: a Multi-Institutional Survey Analysis of Inpatient Workforce Adaptations in the First Phase of COVID-19

Spike protein D614G and RdRp P323L: the SARS-CoV-2 mutations associated with severity of COVID-19

Sympathetic activation: a potential link between comorbidities and COVID-19

High rates of 30-day mortality in patients with cirrhosis and COVID-19

Prognosis of COVID-19 in Patients with Liver and Kidney Diseases: An Early Systematic Review and Meta-Analysis

Obesity and COVID-19: An Italian Snapshot

How to use the nominal group and Delphi techniques

Validation of the Combined Comorbidity Index of Charlson and Elixhauser to Predict 30-Day Mortality Across ICD-9 and ICD-10

Current and New Drugs for COVID-19 Treatment and Its Effects on the Liver

Pharmacological Treatment of Patients with Mild to Moderate COVID-19: A Comprehensive Review

Mathematical Modeling and COVID-19 Forecast in Texas, USA: A Prediction Model Analysis and the Probability of Disease Outbreak

Clinical Characteristics and Morbidity Associated With Coronavirus Disease 2019 in a Series of Patients in Metropolitan Detroit

Intersectional Disparities Among Hispanic Groups in COVID-19

The Impact of Sociodemographic Factors, Comorbidities, and Physiologic Responses on 30-Day Mortality in Coronavirus Disease 2019 (COVID-19) Patients in Metropolitan Detroit

Racial disparities in COVID-19 hospitalizations do not lead to disparities in outcomes